Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | TAAR1 | Q96RJ0 | 4/20 | 0.34 |
| ▸ | HTR2A | P28223 | 4/20 | 0.34 |
| ▸ | HRH1 | P35367 | 3/20 | 0.34 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.32 |
| ▸ | MIF | P14174 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27275025 | 0.88 | POLB (0.37) | LMNATSHRHTR2ASIGMAR1ALDH1A1 | |
| SCHEMBL2686473 | 0.74 | TSHR (0.48) | LMNATSHRTAAR1HTR2AHRH1 | |
| SCHEMBL524106 | 0.71 | AOC3 (0.42) | LMNATSHRTAAR1HTR2AHRH1 | |
| SCHEMBL707144 | 0.70 | LMNA (0.46) | LMNATSHRTAAR1HTR2AHRH1 | |
| SCHEMBL27693934 | 0.69 | LMNA (0.44) | LMNATSHRTAAR1HTR2AHRH1 | |
| SCHEMBL1403768 | 0.68 | POLB (0.41) | LMNAHTR2AHRH1AOC3SIGMAR1 | |
| SCHEMBL4855633 | 0.67 | TSHR (0.40) | TSHRHTR2AHRH1AOC3MAPT | |
| SCHEMBL2272064 | 0.67 | TP53 (0.35) | — | |
| SCHEMBL19470835 | 0.67 | SIGMAR1 (0.41) | HTR2ASIGMAR1ALDH1A1POLBMAPT | |
| SCHEMBL20483517 | 0.66 | HTR2A (0.41) | HTR2ASIGMAR1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090054369-A1 | PHARMACEUTICAL COMPOSITIONS OF SILICON-CONTAINING SUBSTITUTED ADENOSINE NUCLEOSIDE AMIDE ANALOGS | RND PHARMACEUTICALS, INC. (US) | 2009-02-26 | — | — | US | disclosed |
| EP-1919929-A4 | PHARMACEUTICAL COMPOSITIONS OF SILICON-CONTAINING SUBSTITUTED ADENOSINE NUCLEOSIDE AMIDE ANALOGS | RND PHARMACEUTICALS INC (US) | 2008-08-06 | — | — | EP | disclosed |
| EP-1919929-A2 | PHARMACEUTICAL COMPOSITIONS OF SILICON-CONTAINING SUBSTITUTED ADENOSINE NUCLEOSIDE AMIDE ANALOGS | RND Pharmaceuticals, Inc. (US) | 2008-05-14 | — | — | EP | disclosed |
| WO-2007019221-A2 | PHARMACEUTICAL COMPOSITIONS OF SILICON-CONTAINING SUBSTITUTED ADENOSINE NUCLEOSIDE AMIDE ANALOGS | RND PHARMACEUTICALS, INC. (US) | 2007-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054369-A1 | PHARMACEUTICAL COMPOSITIONS OF SILICON-CONTAINING SUBSTITUTED ADENOSINE NUCLEOSIDE AMIDE ANALOGS | SI, SLC29A2, SLC29A1 | LMNA 941/4885TSHR 3201/4885TAAR1 1248/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.